Gargoyle Investment Advisor L.L.C. Continues to Hold Position in Gilead Sciences, Inc. (GILD)
Gargoyle Investment Advisor L.L.C. held its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 9,093 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Gargoyle Investment Advisor L.L.C.’s holdings in Gilead Sciences were worth $644,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. grew its position in Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the period. Penserra Capital Management LLC lifted its holdings in Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares in the last quarter. Webster Bank N. A. lifted its holdings in Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares in the last quarter. American Beacon Advisors Inc. purchased a new position in Gilead Sciences during the first quarter valued at approximately $143,000. Finally, Crestwood Advisors Group LLC lifted its holdings in Gilead Sciences by 11.4% during the second quarter. Crestwood Advisors Group LLC now owns 2,730 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 279 shares in the last quarter. Institutional investors own 73.97% of the company’s stock.
GILD has been the topic of several analyst reports. Morgan Stanley reaffirmed an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Royal Bank Of Canada initiated coverage on shares of Gilead Sciences in a report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target on the stock. Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a report on Tuesday, August 29th. Berenberg Bank set a $86.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, August 29th. Finally, Leerink Swann reaffirmed a “hold” rating and set a $74.00 price target on shares of Gilead Sciences in a report on Tuesday, July 25th. Twelve analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $85.80.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 81.17 on Monday. The company’s 50 day moving average price is $82.48 and its 200-day moving average price is $72.25. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The firm has a market capitalization of $106.00 billion, a P/E ratio of 8.82 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period in the prior year, the business posted $3.08 earnings per share. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.75 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were issued a $0.52 dividend. The ex-dividend date was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
In other news, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 486,819 shares of company stock worth $39,298,919. Company insiders own 1.30% of the company’s stock.
WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/16/gargoyle-investment-advisor-l-l-c-continues-to-hold-position-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.